Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation

NCT01393717 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT01393717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01393717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
October 20, 2011
Completion date
February 1, 2017
Enrollment
57 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent hodgkin lymphoma, refractory hodgkin lymphoma